Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
SY-104
/
Syena
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
SY-104
/
Syena
Trial suspension, Metastases:
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
(clinicaltrials.gov) - Jun 20, 2024
P1
, N=44, Suspended,
Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended
|
|||||||||
SY-104
/
Syena
Enrollment open, Metastases:
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
(clinicaltrials.gov) - May 13, 2024
P1
, N=44, Recruiting,
Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended Suspended --> Recruiting
|
|||||||||
SY-104
/
Syena
Trial suspension, Metastases:
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
(clinicaltrials.gov) - Mar 29, 2024
P1
, N=44, Suspended,
Sponsor: M.D. Anderson Cancer Center
Suspended --> Recruiting Not yet recruiting --> Suspended
|
|||||||||
SY-104
/
Syena
Enrollment open, Trial initiation date:
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov) - Dec 3, 2023
P1/2
, N=44, Recruiting,
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Suspended Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Nov 2023
|
|||||||||
SY-104
/
Syena
New P1 trial, Metastases:
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
(clinicaltrials.gov) - Oct 15, 2023
P1
, N=44, Not yet recruiting,
Sponsor: M.D. Anderson Cancer Center
|
|||||||||
SY-104
/
Syena
New P1/2 trial:
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov) - Oct 3, 2023
P1/2
, N=44, Not yet recruiting,
Sponsor: M.D. Anderson Cancer Center